98%
921
2 minutes
20
Introduction: Syphilis, caused by Treponema pallidum, is a major public health concern, particularly in high-risk populations like incarcerated individuals. Timely diagnosis remains challenging, especially in rural and frontier communities. This study aims to assess the effectiveness of point-of-care (POC) syphilis and HIV testing at the Winner City Jail in South Dakota, a rural correctional facility with a high prevalence of syphilis and HIV risk factors.
Methods: This 12-week cross-sectional study (October 2 to December 19, 2024) tested new intakes from nine counties without prior syphilis or HIV history. POC testing was performed using the Chembio DPP HIV-Syphilis immunoassay, followed by confirmatory testing (RPR for syphilis, NAAT for HIV). Demographic and risk factor data were collected via interviews, and treatment was administered based on diagnosis.
Results: Of the 112 individuals tested, seven (6.3%) had reactive syphilis results, all confirmed by RPR testing. One individual tested positive for HIV on POC, but negative on confirmatory testing. Most syphilis cases were late latent stages (86%), and all were asymptomatic. Risk factors included unprotected sex, substance use, and prior incarceration.
Conclusion: POC testing effectively identified syphilis and HIV in a rural correctional setting, enabling early diagnosis and treatment. While the Chembio test was highly accurate for syphilis, the false positive for HIV emphasizes the importance of confirmatory testing. Expanding this approach to other correctional facilities could reduce STI transmission in high-risk populations. Further studies are needed to assess long-term outcomes and expand testing to other STIs.
Download full-text PDF |
Source |
---|
Sex Transm Dis
September 2025
Departments of Global Health, Medicine, and Epidemiology, University of Washington (JN Wasserheit), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (J Mermin and BP Stoner), and Rietmeijer Consulting (CA Rietmeijer).
Transfusion
September 2025
Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
Introduction: Donors are deferred if they are on antiretroviral medications (ARV) as post-exposure or pre-exposure prophylaxis (PEP or PrEP) for human immunodeficiency virus (HIV). We assessed donor compliance by measuring ARV levels in selected anonymized donor samples collected from September 22, 2022 to December 31, 2024, almost all after the introduction of sexual risk behavior screening.
Methods: EDTA plasma samples collected at the time of donation (retention samples) were retrieved, frozen, and shipped for measurement of tenofovir and emtricitabine.
medRxiv
August 2025
Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Introduction: In Uganda, the spatial distribution of syphilis varies by age, gender, and region. Identifying clusters (subsets of administrative subdivisions) with high syphilis prevalence could boost efforts to eliminate mother-to-child transmission of syphilis. We examined spatial variations and clustering of syphilis prevalence among pregnant young women in Central Uganda.
View Article and Find Full Text PDFOpen Forum Infect Dis
September 2025
Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: The correlation between human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) usage and sexually transmitted infections (STIs) remains equivocal. Limited studies have investigated national STI trends after introducing PrEP. We aimed to examine STI incidence before and after PrEP introduction and explore correlations with PrEP use in the United States.
View Article and Find Full Text PDFBMJ Open
September 2025
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaounde, Cameroon.
Objective: The study was conducted to assess the diagnostic performance of the Hightop Syphilis Rapid Diagnostic Test (RDT) in comparison with the ELISA test used as a reference method.
Design: A laboratory-based cross-sectional and comparative study was conducted to assess the diagnostic performance of the Hightop Syphilis RDT.
Setting: Blood samples obtained from adult participants in eight health facilities were analysed at the National Public Health Laboratory (NPHL), Ministry of Public Health, Yaounde, Cameroon.